Jetzt bestellen : Schweizerische Zivilprozessordnung (Art. 1–352 ZPO sowie Art. 400–408 ZPO)

Biosimilar Drug Product Development

When a biological drug patent expires, alternative biosimilar products are developed. The development of biosimilar products is complicated and involves numerous considerations and steps. The assessment of biosimilarity and interchangeability is also complicated and difficult. Biosimilar Drug Product Development presents current issues for the development of biosimilars and gives detailed reviews of its various stages and contributing factors as well as relevant regulatory pathways and pre- and post-approval issues.

Juni 2020, ca. 496 Seiten, Drugs and the Pharmaceutical Sciences, Englisch
Taylor and Francis
978-0-367-55249-7

Weitere Titel der Reihe: Drugs and the Pharmaceutical Sciences

Alle anzeigen

Weitere Titel zum Thema